INS and type 2 diabetes mellitus: Indeed, the systemic administration of the selective A2BR agonist, BAY60-6583, reduced significantly the plasma glucose, insulin and IL-6 levels, and ameliorated T2DM in HFD mice (Johnston-Cox et al., 2014).